Diligence memo · auto-generated · as of July 2, 2026
Autonomy Bio Inc.
Autonomy Bio Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Autonomy Bio Inc. operates in Biotechnology, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Autonomy Bio Inc. has raised $17M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $17M on 2025-03-17.
Most recent recorded round closed around 2025-03-17.
Valuation (modeled)modeled
Provath models Autonomy Bio Inc. at approximately $89M (range $34M–$140M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.15× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era. Within the normal band (115% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 16 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 65% of Biotechnology peers (4293 compared).
Modeled value ranks above 57% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.